News | November 10, 2023
SMS Pharmaceuticals reports robust Q2FY24 operational performance
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
With this, the company can start selling Ibuprofen in the European markets.
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)